TICKERNOMICS Sign up
Last Update: 2023-10-04 11:37:25
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) https://www.htgmolecular.com
0.34USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-95.13%
HTGM
SPY
36.71%
-99.39%
HTGM
SPY
70.96%
-99.95%
HTGM
SPY
262.36%
HTGM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
0.76
-4.89
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.04
0.12
1.61
-227.44
0.00
0.25
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-485.48
-11.34
-346.76
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.7021
-159.50
-133.56
0.91
Other Earnings and Cash Flow Stats:
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Net Income TTM ($MM) is -21.96
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Operating Income TTM ($MM) is -21.29
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Owners' Earnings Annual ($MM) is -17.52
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Current Price to Owners' Earnings ratio is -0.46
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) EBITDA TTM ($MM) is -20.87
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) EBITDA Margin is -346.76%
Capital Allocation:
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) has paid 0.00 dividends per share and bought back -1.293397 million shares in the past 12 months
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) has reduced its debt by 5.583157 million USD in the last 12 months
Capital Structure:
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Interest-bearing Debt ($MM) as of last quarter is 0
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Annual Working Capital Investments ($MM) are 0
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Book Value ($MM) as of last quarter is 0
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Debt/Capital as of last quarter is 190%
Other Balance Sheet Stats:
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) has 3 million in cash on hand as of last quarter
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) has 6 million of liabilities due within 12 months, and long term debt 4 as of last quarter
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) has 2 common shares outstanding as of last quarter
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) has 0 million USD of preferred stock value
Academic Scores:
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Altman Z-Score is -35.38 as of last quarter
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) largest shareholder is JPMorgan Chase & Co owning 10 shares at 0.00 ($MM) value
Stephen Barat(an insider) Sold 888 shares of HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) for the amount of $710.40 on 2023-06-08
6.54% of HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) is held by insiders, and 0.75% is held by institutions
HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) went public on 2015-05-06
Other HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) financial metrics:
FCF:-20.78
Unlevered Free Cash Flow:-19.85
EPS:-22.74
Operating Margin:-485.48
Gross Profit Margin:-11.34
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-4261.12
Beta:0.91
Buffet's Owners Earnings:-17.52
Price to Owner's Earnings:-0.46
About HTG MOLECULAR DIAGNOSTICS INC ( HTGM ) :
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Tranome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-tranome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.